Companies / Health Care
ABBV
AbbVie
Biotechnology
BiotechnologyAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health64
Growth43
Profitability69
Cash generation100
Balance sheet32
Dilution control76
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)10.3%Revenue growth (FY)8.6%Revenue CAGR (3y)1.8%Gross margin70.2%Operating margin24.6%Net margin6.9%Free cash flow margin29.1%R&D / revenue14.9%Stock comp / revenue1.6%Net debt / operating cash flow3.25xCurrent ratio0.67Diluted share count change0.0%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $56.2B | $58.1B | $54.3B | $56.3B | $61.2B |
| Gross profit | $38.8B | $40.6B | $33.9B | $39.4B | $43.0B |
| Operating income | $17.9B | $18.1B | $12.8B | $9.1B | $15.1B |
| Net income | $11.5B | $11.8B | $4.9B | $4.3B | $4.2B |
| Operating cash flow | $22.8B | $24.9B | $22.8B | $18.8B | $19.0B |
| Capital expenditure | $787M | $695M | $777M | $974M | $1.2B |
| Free cash flow | $22.0B | $24.2B | $22.1B | $17.8B | $17.8B |
| R&D | $6.9B | $6.5B | $7.7B | $12.8B | $9.1B |
| Stock-based comp | $692M | $671M | $747M | $911M | $955M |
| Buybacks | $934M | $1.5B | $2.0B | $1.7B | $980M |
| Dividends | $9.3B | $10.0B | $10.5B | $11.0B | $11.7B |
| Cash | $9.7B | $9.2B | $12.8B | $5.5B | $5.2B |
| Total debt | $76.0B | $63.1B | $59.2B | $66.8B | $67.0B |
| Equity | $15.4B | $17.3B | $10.4B | $3.3B | -$3.3B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.